Histone deacetylases (HDACs) are emerging as exciting new targets for drug development, particularly for cancer and metabolic diseases. Because they exert control over gene transcription and ...

Alzheimer disease is a progressive neurodegenerative disorder that impairs memory and mental function. It is the most common form of dementia, accounting for 60–70% of cases, and its prevalence is ...

Tenaya’s Highly Selective HDAC6 Inhibitor TN-301 Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correcting ...

The July approval of the histone deacetylase (HDAC) inhibitor Beleodaq (belinostat) marks the third HDAC inhibitor to gain registration in the US and the first in almost five years—all for treating ...

Checkpoint inhibitors play a critical role in immunotherapy. Unfortunately, they don’t work all the time. For reasons that have been largely unknown, some patients respond to checkpoint inhibitor ...

A drug with a past life as a potential anti-cancer agent might someday have a new job as "the pill" for men, new data in mice suggest. In a journal article published Feb. 20 in Proceedings of the ...

As gene regulation changes in Alzheimer’s disease, scientists believe that histone deacetylases (HDACs) go into overdrive, shutting down transcription of certain genes. Consequently, several research ...

Several new immunotherapeutic antibodies that inhibit checkpoint receptors on T cells to restimulate the immune system to target tumors have been approved to treat advanced stage lung cancer and ...

Preclinical studies suggest that blocking histone deacetylases, which modulate gene transcription, could potentially treat neurodegeneration, but in practice, the theory has not lived up to its ...

Pancreatic cancer is one of the deadliest cancers - only about one in eight patients survives five years after diagnosis. Those dismal statistics are in part due to the thick, nearly impenetrable wall ...